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Materials and Methods

Biological Samples
Urine samples were collected from nine healthy male volunteers (ages 29-52 years, mean 37) with no history of drug or alcohol abuse, after oral intake of the following benzodiazepines: alprazolam (2 mg, n = 6), chiordiazepoxide (25 mg, n = 5), flurntrazepam (1 mg, n = 6), lorazepam (3.75 mg, n = 6), nitrazepam (5 mg, n = 6), and triazolam (0.25 mg, n = 6). The subjects ingested benzodiazepine at 2200 h after collecting a control sample of urine. At each time of collection, which occurred at random time points, urine was saved both in a separate 10-mL volume and pooled in three intervals (0-12 h, 12-18 h, 18-24 h) during the first 24 h. The interval between 24 and 32 h was covered by collecting the morning urine at about 32 h after the intake. All urine was collected in plastic containers.
After the arrival to the laboratory (within 48 h of drug intake), the samples were stored at -80 #{176}C and analyzed within one month. The wash-out period 
Results
EMIT
The unmodified EMiT (Table 3) . However, the modified assay procedure improved the detectability, completely identifying this compound at all time points. Chlordiazepoxide intake was detected in all five subjects at 32 h with the modified FP!A (Table 3) . Flunitrazepam (Table 3) .
The effect of the enzymatic hydrolysis on the response in therapeutic doses (7) (8) (9) . We recently focused our attention on the detection of oxazepam intake and showed that both the EMIT and triazolam. However, the hydrolysis procedure effectively increased the sensitivity of the FPIA system and, in combination with a lower cutoff value (100 g/L, i.e., our modified method), the FPIA assay offered a powerful system for general benzodiazepine detection (Table 3 ). The results for pooled urine (Table 3) The routine application of a lower cutoff value in the FPIA has also been suggested by others (8 
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